Outcomes of Patients with Metastatic Melanoma Treated with Molecularly Targeted Agents in Phase I Clinical Trials

Publisher： Karger

E-ISSN： 1423-0232|81|2|135-140

ISSN： 0030-2414

Source： Oncology, Vol.81, Iss.2, 2011-10, pp. : 135-140

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical Benefit of New Targeted Agents in Phase I Trials in Patients with Advanced Colorectal Cancer

By  

Oncology, Vol. 76, Iss. 3, 2009-01 ,pp. : 151-156

Karger

Access to resources Recommend Favorite

Creatinine Clearance Is Associated with Toxicity from Molecularly Targeted Agents in Phase I Trials

By  

Oncology, Vol. 83, Iss. 4, 2012-08 ,pp. : 177-182

Karger

Access to resources Recommend Favorite

Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors

By  

CANCER, Vol. 120, Iss. 11, 2014-06 ,pp. : 1695-1701

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma

By  

CANCER, Vol. 119, Iss. 21, 2013-11 ,pp. : 3821-3829

John Wiley & Sons Inc

Access to resources Recommend Favorite

Enrollment in Clinical Trials Correlates with Improved Survival in Metastatic Melanoma

By  

Oncology, Vol. 81, Iss. 5-6, 2012-01 ,pp. : 403-409

Karger

Access to resources Recommend Favorite